17β-estradiol replacement therapy induces eNOS, nNOS and estrogen receptor β in hypophysectomized rats with inflamed footpads


Article ID: 4598
Vol 33, Issue 5, 2019
DOI: https://doi.org/10.23812/19-64A
Received: 5 March 2019; Accepted: 5 March 2019; Available online: 8 November 2019; Issue release: 8 November 2019

Abstract

Nitric oxide (NO) plays a key role in inflammation. It is partly produced by three forms of NOS: eNOS of inflammatory cells, nNOS of neural cells and iNOS (inducible isoform). Estrogens can cause an anti-inflammatory effect, although it is not yet clear through which NOS isoforms. The aim of this study was to evaluate the role of the different NOS isoforms, as well as estrogen receptors (ERs) α and β, on the anti-inflammatory effects of estrogens. To avoid the influence of endogenous glucocorticoids or sexual hormones, male rats were hypophysectomized. Animals were segregated into two control groups (no-treatment control group and SHAM-operated animals) and three hypophysectomized groups (no-hormonal treatment, with estradiol-17β, or with testosterone replacement treatment). Freunds complete adjuvant (1 mg) was administered to the footpad of all animals. Measurements were made based on footpad inflammation (with a plethysmometer) such as eNOS, nNOS, iNOS and ER α and β protein expression (by immunohistochemistry principle/method) on days 1, 7 and 14. Only estradiol decreased inflammation, accompanied by increased levels of eNOS and nNOS and differential expression of ERs α and β in the inflammatory infiltrate. The higher levels of estradiol-induced eNOS and nNOS ocurred perhaps through the activation of ER β.


Keywords

eNOS;iNOS;nNOS;estradiol;as estrogen receptors α and β;hypothalamic-pituitary-adrenal axis;inflammation


References

Supporting Agencies



Copyright (c) 2019




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).